KemPharm Inc (KMPH) : Arete Wealth Advisors reduced its stake in KemPharm Inc by 20.74% during the most recent quarter end. The investment management company now holds a total of 827,745 shares of KemPharm Inc which is valued at $3,319,257 after selling 216,599 shares in KemPharm Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.KemPharm Inc makes up approximately 1.96% of Arete Wealth Advisors’s portfolio.
Other Hedge Funds, Including , Endurant Capital Management Lp boosted its stake in KMPH in the latest quarter, The investment management firm added 64,700 additional shares and now holds a total of 169,586 shares of KemPharm Inc which is valued at $680,040. KemPharm Inc makes up approx 0.19% of Endurant Capital Management Lp’s portfolio.Spark Investment Management boosted its stake in KMPH in the latest quarter, The investment management firm added 93,284 additional shares and now holds a total of 141,109 shares of KemPharm Inc which is valued at $565,847. KemPharm Inc makes up approx 0.05% of Spark Investment Management’s portfolio.Credit Suisse Ag reduced its stake in KMPH by selling 24,127 shares or 69.99% in the most recent quarter. The Hedge Fund company now holds 10,345 shares of KMPH which is valued at $41,483. Tower Research Capital (trc) sold out all of its stake in KMPH during the most recent quarter. The investment firm sold 689 shares of KMPH which is valued $2,763.Blackrock Investment Management boosted its stake in KMPH in the latest quarter, The investment management firm added 1,062 additional shares and now holds a total of 2,049 shares of KemPharm Inc which is valued at $8,216.
KemPharm Inc opened for trading at $4.36 and hit $4.55 on the upside on Thursday, eventually ending the session at $4.44, with a gain of 2.78% or 0.12 points. The heightened volatility saw the trading volume jump to 57,580 shares. Company has a market cap of $65 M.
KemPharm Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of new molecular entity (NME) prodrugs. The Company through its Ligand Activated Therapy (LAT) platform technology creates NME prodrug product candidates. The Company’s NME prodrug product candidates include KP201/APAP KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder (ADHD) and KP303 for the treatment of central nervous system (CNS) disorders. The Company’s product’s KP201/APAP is in clinical trial stage and KP511/ER KP415 KP606/ER and KP303 are in preclinical trail stage.